Enhanced bioavailability of orally administered antisense oligonucleotide to nuclear factor kappa B mRNA after microencapsulation with albumin

References

• Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci 1978;75:285–8
   PubMed Web of Science ®Google Scholar
• Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of phosporothioates in mice. Proc Nat Acad Sci 1999;88:7595–9
   Google Scholar
• Crook ST, Bennett CF. Progress in antisense oligonucleotides therapeutics. Ann Rev Pharmacol Toxicol 1996;36:107–29
   PubMed Web of Science ®Google Scholar
• Xie J, Ma C, Lin J, et al. An anionic long-circulating liposome that improves radioiodinated antisense oligonucleotide delivery in vitro and in vivo. Adv Polym Technol 2012;31:20–8
   Web of Science ®Google Scholar
• Yang X, Peng Y, Yu B, et al. A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery. Molec Pharmaceutics 2011;8:709–15
   PubMed Web of Science ®Google Scholar
• Han S-E, Kang H, Shim GY, et al. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. J Drug Target 2009;17:123–32
   PubMed Web of Science ®Google Scholar
• Karinaga R, Anada T, Minari J, et al. Galactose-PEG dual conjugation of β-(1 → 3)-D-glucan schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptake. Biomaterials 2006;27:1626–35
   PubMed Web of Science ®Google Scholar
• Berdugo M, Valamanesh F, Andrieu C, et al. Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucl Acid Drug Develop 2003;13:107–14
   PubMedGoogle Scholar
• Lee KE, Cho SH, Lee HB, et al. Microencapsulation of lipid nanoparticles containing lipophilic drug. J Microencapsul 2003;20:489–96
   PubMed Web of Science ®Google Scholar
• Martinho N, Damge C, Reis CR. Recent advances in drug delivery systems. J Biomater Nanobiotechnol 2011;2:510–26
   Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis of microspheres. J Control Rel 2002;79:29–40
   PubMed Web of Science ®Google Scholar
• Thiele L, Merkle HP, Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharmaceut Res 2003;20:221–8
   PubMed Web of Science ®Google Scholar
• Makino K, Yamamoto N, Higuchi K, et al. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of size and surface properties of the microspheres. Colloids Surf B: Biointerfaces 2003;27:33–9
   Web of Science ®Google Scholar
• Yamamoto N, Fukai F, Ohshima H, et al. Dependence of phagocytic uptake of polystyrene microspheres by differentiated HL60 upon the size and surface properties of the microspheres. Colloids Surf B: Biointerfaces 2002;25:157–62
   Web of Science ®Google Scholar
• Bhowmik T, D'Souza B, Uddin MN, D’Souza MJ. Oral delivery of microparticles containing plasmid DNA encoding hepatitis-B surface antigen. J Drug Target 2012;20:364–71
   PubMed Web of Science ®Google Scholar
• Akhter S, Lewis JK. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained release biodegradable polymer microspheres. Int J Pharmaceut 1997;151:57–67
   Web of Science ®Google Scholar
• D'Souza MJ, DeSouza P. Preparation and testing of cyclosporine microsphere and solution formulations in the treatment of polyarthritis in rats. Drug Develop Indust Pharmacy 1998;24:841–52
   PubMed Web of Science ®Google Scholar
• Siwale RC, Oettinger CW, Pai BS, et al. Formulation and characterization of Catalase in albumin microspheres. J Microencapsul 2006;24:337–48
   Google Scholar
• Uddin MN, Do DP, Balakrishna PS, et al. A methodology for quantitation and characterization of oligonucleotides in albumin microspheres. Analyst 2009;134:1483–9
   PubMed Web of Science ®Google Scholar
• Akalkotkar AM, Tawde SA, Chablani L, D'Souza MJ. Oral delivery of particulate prostratecancer vaccine: in vitro and in vivo evaluation. J Drug Target 2012;20:338–46
   PubMed Web of Science ®Google Scholar
• Bhowmik T, D’Souza B, Shashidharamurthy R, et al. A novel microparticulate vaccine for melanoma cancer using transdermal delivery. J Microencapsul 2011;28:294–300
   PubMed Web of Science ®Google Scholar
• D’Souza MJ, Jin Z, Oettinger CW, Milton GV. Prevention of lethality and suppression of proinflammatory cytokines in experimental septic shock by microencapsulated CNI-1493. J Interferon Cytokine Res 1999;19:1125–33
   PubMed Web of Science ®Google Scholar
• D'Souza MJ, Jin Z, Oettinger CW. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-κB. J Interferon Cytokine Res 2005;25:311–20
   PubMed Web of Science ®Google Scholar
• Oettinger CW, D’Souza MJ, Akhavein N, et al. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kappaB. J Microencapsul 2007;24:337–48
   PubMed Web of Science ®Google Scholar
• Siwale RC, Oettinger CW, Addo R, et al. The effect of intracellular delivery of catalase and antisense oligonucleotides to NF-kappaB using albumin microcapsules in the endotoxic shock model. J Drug Target 2009;17:701–9
   PubMed Web of Science ®Google Scholar
• Uddin MN, Siddiq A, Oettinger CW, D’Souza MJ. Potentiation of pro-inflammatory cytokine suppression and survival by microencapsulated dexamethasone in the treatment of experimental sepsis. J Drug Target 2011;19:752–60
   PubMed Web of Science ®Google Scholar
• Gayakwad SG, Bejugam NK, Akhavein N, et al. Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres. J Microencapsul 2009;26:692–700
   PubMed Web of Science ®Google Scholar
• Aynie L, Vauthier C, Foulquier M, et al. Development of quantitative polyacrylamide gel electrophoresis analysis using a multi-channel radioactive counter for the evaluation of oligonucleotide-bound drug carrier. Anal Biochem 1996;240:202–9
   PubMed Web of Science ®Google Scholar
• Arnedo A, Campanero MA, Espuelas S, et al. Analysis of natural food pigments by capillary electrophoresis. J Chromatogr A 2000; 871:311–20
   PubMedGoogle Scholar
• Wei X, Dai G, Marcucci G, et al. Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase. Pharm Res 2006;23:1251–64
   PubMed Web of Science ®Google Scholar
• Lanke SS, Gayakwad SG, Strom JG, D’Souza MJ. Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system. J Microencapsul 2009;26:493–500
   PubMed Web of Science ®Google Scholar
• Bejugam NK, Gayakwad G, Uddin AKM, D’Souza MJ. Microencapsulation of protein into biodegradable matrix: a smart solution cross-linking technique. J Microencapsul October, 2012 [Online]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23098577
   Google Scholar
• Dias N, Stein CA. Antisense oligonucleotides: basic concept and mechanisms. Molec Cancer Therapeut 2002;1:347–55
   PubMed Web of Science ®Google Scholar
• Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science 1993;261:1004–12
   PubMed Web of Science ®Google Scholar
• DeRosa G, Maiuri MC, Ungaro F, et al. Enhanced intracellular uptake and inhibition of NF-κB activation by decoy oligonucleotide released from PLGA microsphere. J Gene Med 2005;7:77–81
   Google Scholar
• Deleavey GF, Watts JK, Damha MJ. Chemical modification of siRNA. Curr Protocols Nucleic Acid Chem 2009;16:1–22
   PubMedGoogle Scholar
• Walter AE, Turner DH, Kim J, et al. Coaxial sacking of helixes enhances binding of oligonucleotides and improves prediction of RNA folding. Proc Natl Acad Sci 1994;91:9218–22
   PubMed Web of Science ®Google Scholar
• Xiang G, Leaf H. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 1996;35:1027–36
   PubMed Web of Science ®Google Scholar
• Loke SL, Stein CA, Zhang XH, et al. Characterization of oligonucleotide transport in living cells. Proc Natl Acad Sci 1989;86:3474–8
   PubMed Web of Science ®Google Scholar
• Arora V, Knapp DC, Reddy MT, et al. Bioavailability and efficacy of antisene morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J Pharmaceut Sci 2002;9:1009–18
   Google Scholar
• Raoof AA, Chiu P, Ramtoola Z, et al. Oral bioavailability and multiple dose tolerability of an antisene oligonucleotide tablet formulated with sodium caprate. J Pharmaceut Sci 2003;93:1431–9
   Web of Science ®Google Scholar
• Akhavein N, Oettinger CW, Gayakwad SG, et al. Treatment of adjuvant arthritis using microencapsulated antisense NF-κB oligonucleotides. J Microencapsul 2009;26:223–34
   PubMed Web of Science ®Google Scholar